March 20 (Reuters) – The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb’s combination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin’s lymphoma.
The therapy, branded as Opdivo, is already approved to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer.
The FDA said the newly approved regimen combines Opdivo with doxorubicin, vinblastine and dacarbazine, offering a new frontline option for advanced-stage disease.
Hodgkin’s lymphoma is a cancer of the lymphatic system that often appears as painless, swollen lymph nodes in the neck, chest or armpits.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)
Comments